Comparing 2 cm vs. 1 cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2 mm: A multicenter retrospective study of 336 Japanese patients
- PMID: 40570594
- DOI: 10.1016/j.ejso.2025.110264
Comparing 2 cm vs. 1 cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2 mm: A multicenter retrospective study of 336 Japanese patients
Abstract
Introduction: Multiple randomized trials comparing wide local excision (WLE) with different peripheral margins have established recommended peripheral margins according to Breslow thickness (BT) in the National Comprehensive Cancer Network (NCCN) Guidelines. However, these clinical trials included only a small number of patients with acral melanoma (AM). Therefore, we aimed to compare the prognosis of different WLE peripheral margin cohorts with invasive sole AM.
Materials and methods: We conducted a multi-institutional retrospective study of patients with sole AM and a BT greater than 2 mm. Survival outcomes were compared between two groups: those excised with a peripheral margin of 2 cm, as recommended by the NCCN Guidelines, and those excised with a peripheral margin of 1 cm.
Results: This study included 336 patients (2 cm margin: n = 226; 1 cm margin, n = 110) with a median follow-up period of 43.1 months. In multivariate analyses, a peripheral margin of 1 cm did not negatively affect survival (local recurrence-free survival [LRFS]: hazard ratio [HR] 1.19, P = 0.38; disease-free survival [DFS]: HR 1.05, P = 0.75). Survival after propensity score matching showed no significant differences between the matched groups (each group: n = 103; 5-year LRFS: 70.6 % vs. 59.3 %, P = 0.13; 5-year DFS: 47.4 % vs. 54.0 %, P = 0.63).
Conclusion: A peripheral margin of 1 cm did not negatively influence the prognosis of patients with a sole AM and a BT greater than 2 mm. Narrower surgical margins may be acceptable to minimize morbidity without compromising survival.
Keywords: Breslow thickness; Cutaneous melanoma; Surgical margin; Wide local excision; acral melanoma.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest Naoya Yamazaki has received research funding from Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Ono Pharma, and Takara Bio, and has served as a consultant and/or received honoraria from BMS, MSD, Novartis, and Ono Pharma. Shigeto Matsushita has received honoraria from BMS, MSD, Novartis, and Ono Pharma. Dr. Yasuhiro Nakamura has received research funding and has served as a consultant and/or received honoraria from Alexion Pharma, Bristol-Myers Squibb, Dai-ichi Sankyo, HUYA Bioscience International, Kyowa Kirin, LEO Pharma, Maruho, MSD, Novartis Ono Pharma, Pierre Fabre, Sanofi, Sun Pharma, and Tanabe-Mitsubishi Pharma. The other authors have no conflicts of interest to disclose.
Similar articles
-
Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis.Can J Surg. 2003 Dec;46(6):419-26. Can J Surg. 2003. PMID: 14680348 Free PMC article.
-
Prognosis of a deep excision margin within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective study.Surgery. 2025 Jul 22;186:109573. doi: 10.1016/j.surg.2025.109573. Online ahead of print. Surgery. 2025. PMID: 40700875
-
Is the ≥1 cm Width of the Resection Margin in Benign and Borderline Phyllodes Tumor Necessary to Reduce Recurrence?Breast J. 2024 Aug 2;2024:1432313. doi: 10.1155/2024/1432313. eCollection 2024. Breast J. 2024. PMID: 39742370 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin.JAMA Dermatol. 2024 Aug 1;160(8):874-877. doi: 10.1001/jamadermatol.2024.1878. JAMA Dermatol. 2024. PMID: 38922604 Free PMC article.
LinkOut - more resources
Full Text Sources